Latest news with #JohnYang
SBS Australia
11-08-2025
- Business
- SBS Australia
Watch PBS NewsHour: Monday August 11, 2025
News And Current Affairs, News - Overseas 22m Expires in 1 week Analysis of national and international news, as well as in-depth reporting on topics ranging from education and politics to technology and finance. Hosted by John Yang for the Public Broadcasting Service (PBS) in the United States. Play Monday August 11, 2025 22m
Associated Press
04-08-2025
- Business
- Associated Press
Treez Launches Digital Wallet Loyalty Platform
SAN FRANCISCO--(BUSINESS WIRE)--Aug 4, 2025-- Treez, the leading enterprise commerce platform powering over $5 billion in annualized transactions, today announced the launch of Treez Loyalty, a digital wallet-based customer engagement platform developed in partnership with Sticky Cards. The new solution overcomes barriers with traditional SMS carrier restrictions and low mobile application adoption, enabling cannabis retailers a direct and cost-effective way to drive repeat business and build stronger customer engagement. Customer Loyalty at the Center of Growth Retailers are under growing pressure to keep customers coming back. Rising acquisition costs and limited marketing options make customer retention one of the few levers retailers can reliably control. Strict industry advertising rules add to the challenge, leaving operators looking for more direct, cost‑effective ways to build loyalty. 'Cannabis retailers have been forced to operate with one hand tied behind their backs when it comes to customer engagement,' said John Yang, CEO and Co-Founder of Treez. 'Treez Loyalty fundamentally changes the game by delivering enterprise marketing capabilities through a friction-free digital wallet experience. Treez Loyalty gives retailers modern tools to compete and grow in an increasingly sophisticated market.' A Smarter Loyalty Platform Treez Loyalty leverages Apple Wallet, Google Wallet, and a Progressive Web App to deliver: Compelling Economics for Retailers Pilot programs are already delivering measurable ROI: Part of a Growing Platform This launch reinforces Treez's market position as the enterprise platform of choice for high-volume cannabis retailers. Treez continues to expand its integrated suite of solutions, including: Together, these solutions give high volume retailers an integrated operating experience. Availability Treez Loyalty will begin rolling out to select enterprise retailers this quarter. It will be available as both a standalone product and as part of Treez's comprehensive retail platform. About Treez Treez is the leading enterprise commerce platform for cannabis retail, providing integrated point of sale, ecommerce, payments, and analytics solutions to the industry's highest-volume operators. Backed by leading software and fintech investors including Long Ridge Equity Partners, Kayne Partners, Synchrony, and Intrinsic, Treez is headquartered in San Francisco. For more information, visit View source version on CONTACT: Lorretta Gasper Wind Rose Communications for Treez [email protected] 404-216-0643 KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: SOFTWARE NATURAL RESOURCES SPECIALTY TECHNOLOGY CONSUMER CANNABIS OTHER CONSUMER RETAIL SOURCE: Treez Copyright Business Wire 2025. PUB: 08/04/2025 10:23 AM/DISC: 08/04/2025 10:23 AM
Yahoo
21-05-2025
- Business
- Yahoo
IBA and PET Pharm Bio sign contract to install a Cyclone® IKON in Taiwan
The Cyclone® IKON is IBA's high energy and high-capacity cyclotron which offers the largest energy spectrum for the production of PET and SPECT isotopes from 13 MeV to 30 MeV Louvain-La-Neuve, Belgium, May 21, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of radiopharmaceutical production solutions, announces it has signed a contract with PET Pharm Bio to install a PET and SPECT isotopes production center in Taipei, Taiwan. PET Pharm Bio is a manufacturer and provider of medical isotopes used for oncology diagnosis and therapy. The radioisotopes production center will be equipped with a Cyclone® IKON and will include beam lines, solid targets for SPECT and PET isotopes, as well as radiochemistry solutions. The new PET Pharm Bio radiopharmacy will also benefit from IBA IntegraLab® design and third parties integration services ensuring the full GMP compliance of this production center. This new GMP radiopharmacy will be used to produce novel radiopharmaceuticals for applications in theranostics and targeted therapies, including Germanium-68 (used for Germanium-68/Gallium-68 generators), Iodine-123, Thalium-201, Zirconium-89 and Copper-64. The typical end-user price for a Cyclone® IKON solution is between EUR 10 and 15 million, depending on options and associated equipment. John Yang, Chairman of PET Pharm Bio Taiwan R.O.C., said: 'With IBA Cyclone® IKON 30 MeV as the backbone, which makes the production of numerous theranostic radiopharmaceuticals possible, PET Pharm Bio will be quickly propelled into a new territory previously not existing in Taiwan and Southeast Asia. As the largest radiopharmaceutical GMP manufacturer in Taiwan, partnering with IBA elevates us to the rank of developers of innovative radiopharmaceuticals targeting not only markets in Taiwan, but globally.' Charles Kumps, President of IBA RadioPharma Solutions, added: 'We are pleased to partner with PET Pharm Bio and support them in their ambition to produce and deliver key radiopharmaceuticals to advance nuclear medicine applications in the region. There are a growing number of clinical trials and an increase in new radiotherapeutic molecule developments, with many companies recognizing the great potential of theranostics. The acquisition of IBA's Cyclone® IKON solution will enable PET Pharm Bio to leverage a versatile and high-power system at minimal running costs.' ***ENDS*** About PET Pharm Bio Taiwan R.O.C. Since its establishment in year 2011, PET Pharm Bio has been dedicated to the research, development, and production of radiopharmaceuticals, providing high-quality medical solutions to patients nationwide. We strive to be the best partner for nuclear medicine physicians and patients alike. Our vision is to advance precision diagnosis and treatment in nuclear medicine, improve patient health, and become a leader in the radiopharmaceutical field both in Taiwan and globally. With innovation, quality, and service at our core, we are committed to driving the future of radiopharmaceuticals forward. About IBA IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as the most advanced form of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,100 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance. IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters and Bloomberg More information can be found at: CONTACTS Olivier LechienCorporate Communication Director+32 10 475 890communication@ ICR HealthcareAmber Fennell, Angela Gray, Chris Welsh+44 (0) 20 3709 5700IBA@ Attachment 250521-Cyclone_IKON-Taiwan-ENb
